Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
about
Role of cytochrome P450 in drug interactionsMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsOpioid metabolismTerbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjectsPlasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patientsA systematically combined genotype and functional combination analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in different geographic areas of mainland China--a basis for personalized therapyInherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquineEvaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation.Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system.Clinically significant pharmacokinetic drug interactions between antiepileptic drugs.Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.Gender-related differences in pharmacokinetics and their clinical significance.The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis.Pharmacogenetics and psychopharmacotherapy.CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Pharmacogenomics: a systems approach.Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.Frequency of human CYP2D6 mutant alleles in a normal Chinese population.Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19Cytochrome P4502D6 genotype does not determine response to clozapine.Cytochrome P450 polymorphisms and response to antipsychotic therapy.A review and assessment of potential sources of ethnic differences in drug responsiveness.Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability.Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with CaucasiansMetabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy SwedesThe role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrelPharmacogenomics: bench to bedside.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Relative bioavailability and pharmacokinetic comparison of two different enteric formulations of omeprazole.Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype.CYP2C19 drug-drug and drug-gene interactions in ED patients.Options for treating postherpetic neuralgia in the medically complicated patient.Paranoid psychosis and myoclonus: flecainide toxicity in renal failure.
P2860
Q21245066-F85B1328-5DF5-4EB6-94E8-E52063AB5C77Q24683013-5D47BE2E-F7FF-4293-87EC-4F9EA33912B9Q28250437-1FBD4889-81AD-49D0-84EA-26591A513370Q28347094-EF036749-04FE-4E2B-8CFB-A99ACF6CF5DFQ28354167-A45A708E-437E-46ED-B9F8-87D58F18A4FAQ28533992-6AFA912A-06B3-450B-B3C7-563769A41794Q28609999-26B7A7B9-B778-419A-B8E0-0289E32309D7Q31806016-BA203D94-0A3A-4552-87D4-A11BCC6CDBEFQ33538523-4E8198D7-9BDB-4FD1-AE49-7908A7941453Q33630990-32ECAB63-F9EE-4C8C-A5A8-47FE0A4DF383Q33668831-8CC678C1-5D83-436C-B8B1-2568F05C9B54Q33734852-73DF7BD7-37C6-44B6-819E-188EA83EC6AFQ33785861-7351D4D1-3D04-4B72-BFE5-B37F88D5E065Q33924143-555AB99B-B4D1-4F71-BC06-530A20B1EF75Q33962212-89D60D3B-42DE-43E5-AD19-145DFA82B0BFQ34125166-ADE09FFF-EF19-4E61-A4BD-C8162C2911DBQ34137575-C3FCD2D0-3646-4F6D-B979-990EDA32F3F6Q34331552-1B354F4C-230D-4BCB-9FF1-A69F8A0DAA3AQ34345510-ADBACEDE-F104-4037-BE13-0678764AE025Q34345969-E0A0BA77-CFD4-4AA9-A750-62364A1AEDD4Q34346439-6F4D7C3A-D8AD-4A6B-A969-DF3CBD9AB703Q34346620-465A088A-0001-4DE0-A527-76007AFCA819Q34347232-A7545267-1B4A-444C-A2A8-A08F70353DFEQ34347496-3D8DB8BA-F55D-457C-96AA-57D31E3AE516Q34612118-2969F637-0F02-4720-B00B-B30A90E74B21Q35217493-B9EDF405-1F26-48E1-80B4-F49AA6FD8880Q35287206-63F9EA26-A563-4513-80D5-97327CA6F86CQ35547234-0F12757B-96ED-4E0A-872E-2E9D9AC1EF17Q35825164-271A1372-E972-40F9-8029-C6DD61DCA54BQ35825400-707E7C7B-B891-458E-93B3-1EB66447DBBCQ35825761-2C85F6AF-54AC-4ACA-B2F8-29FF9A33FCF1Q35827129-361FA9F4-0443-46C1-BCD4-F82923D8F6F6Q35876017-38A79B40-D63D-48B3-895E-35E4FC56B7C6Q35876954-2A0D379C-C271-4E81-BD22-9AE4701416EDQ35946393-3804BA6D-663E-4099-B333-DF0AB808DB31Q36053715-ADDCD7BF-F1F1-486D-A80E-596EF453FB4EQ36684887-FED34A7C-6DFC-418B-B58F-193840AF8CDFQ36930041-9449D128-247D-4B26-8A30-AB12DE84E6D7Q37120711-6EB2C838-4120-428C-A40E-46287A67A6CCQ37122997-6FC7AB2C-A045-4D17-B622-A1C456042DF2
P2860
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@ast
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@en
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@nl
type
label
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@ast
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@en
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@nl
prefLabel
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@ast
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@en
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@nl
P2093
P356
P1476
Pronounced differences between ...... debrisoquin and S-mephenytoin.
@en
P2093
Bertilsson L
Reviriego J
Sjöqvist F
P304
P356
10.1038/CLPT.1992.38
P407
P577
1992-04-01T00:00:00Z